FindTrial
Sign In

Effect of SGLT2 Inhibitors on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Study Using an Medical Record Database

Effect of SGLT2 Inhibitors on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Retrospective Observational Study Using the Japan Diabetes Research and Management Database (J-DREAMS) - Effect of SGLT2 Inhibitors on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Study Using a Nationwide Diabetes Database Based on Medical Records

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000059645
Enrollment
Unknown
Registered
2025-11-05
Start date
2025-11-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes, Non-Alcoholic Fatty Liver Disease

Interventions

None listed

Sponsors

National Institute for Health Security
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who newly initiated treatment with SGLT2 inhibitors or other oral antidiabetic drugs and continued the therapy for more than three years

Exclusion criteria

Exclusion criteria: Patients treated with pioglitazone or GLP-1 receptor agonists

Design outcomes

Primary

MeasureTime frame
Changes in the Fibrosis-4 Index (FIB-4 Index) before and at 1, 2, and 3 years after administration of SGLT2 inhibitors or other antidiabetic drugs.—

Countries

Japan

Contacts

Public ContactHisayuki Katsuyama

National Kohnodai Medical Center Department of Diabetes, Endocrinology and Metabolism

katsuyama.h@jihs.go.jp0473723501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026